Browsing by author "AHern, Roger"
Now showing items 1-5 of 5
-
Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer.
Barton, S; Zabaglo, L; A'Hern, R; Turner, N; Ferguson, T; et al. (SPRINGERNATURE, 2012-05-22)BACKGROUND: The immunohistochemical (IHC) 4+C score is a cost-effective prognostic tool that uses clinicopathologic factors and four standard IHC assays: oestrogen receptor (ER), PR, HER2 and Ki67. We assessed its utility ... -
Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast.
Natrajan, R; Wilkerson, PM; Marchiò, C; Piscuoglio, S; Ng, CKY; et al. (WILEY, 2014-04-01)Micropapillary carcinoma (MPC) is a rare histological special type of breast cancer, characterized by an aggressive clinical behaviour and a pattern of copy number aberrations (CNAs) distinct from that of grade- and oestrogen ... -
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Mateo, J; Carreira, S; Sandhu, S; Miranda, S; Mossop, H; et al. (MASSACHUSETTS MEDICAL SOC, 2015-10-29)BACKGROUND: Prostate cancer is a heterogeneous disease, but current treatments are not based on molecular stratification. We hypothesized that metastatic, castration-resistant prostate cancers with DNA-repair defects would ... -
Short-term presurgical treatment for all?
Dowsett, M; Salter, J; Hills, M; Detre, S; A'Hern, R; et al. (BIOMED CENTRAL LTD, 2007-01-01) -
Who would have thought a single Ki67 measurement would predict long-term outcome?
Dowsett, M; A'Hern, R; Salter, J; Zabaglo, L; Smith, IE (BMC, 2009-01-01)